Westminster, CO, Oct. 4, 2017 – Flagship Biosciences was honored to receive the award for Best Poster in the Research Category at the Pathology Visions 2017 annual conference in San Diego, CA for their poster on Evaluating Image Analysis Approaches Toward “Harmonization” of PD-L1 Assays. The poster describes how Flagships’ proprietary Computational Tissue Analysis (cTA™) platform could be used to develop an approach to harmonize the interpretation of individual PD-L1 diagnostic tests. A proof-of-concept study involving non-small cell lung cancer (NSCLC) patient samples was conducted using FDA approved staining tests. The cTA platform was then used to identify tissue and cell-specific Biofeatures™ to generate digital scores for PD-L1 test comparison. Based on this proof-of-concept study, Flagship’s cTA platform provides a method to potentially enable harmonization of PD-L1 assays.
About Flagship Biosciences
Flagship Biosciences helps drug developers confidently define their path to success. By leveraging our unique computational Tissue Analysis (cTA™) and Data-Driven-Decision Support Platform, we provide quantitative and contextual tissue interpretation to make timely decisions. For more information on how Flagship accelerates drug development, please visit the Company’s website: www.flagshipbio.com.
Marketing Associate, Flagship Biosciences, Inc.